Recombinant Human Interleukin-17F (rHuIL-17F)
Catalogue Numbers: PR1064-5, PR1064-25
Sizes: 5µg, 25µg
Source: Escherichia coli
Molecular Weight: A disulfide-linked homodimer of 30.1kDa, consisting of two 133 amino acid polypeptide chains.
Purity: >95% by SDS-PAGE and HPLC analyses.
Biological Activity: Measured by its ability to induce IL-6 production by NHDF cells, it’s fully biologically active when compared to standard.
Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation: Lyophilized from a 0.2mm filtered concentrated solution in PBS, pH 7.4.
AA Sequence: MRKIPKVGHT FFQKPESCPP VPGGSMKLDI GIINENQRVS MSRNIESRST
SPWNYt VTWD PNRYPSEVVQ AQCRNLGCIN AQGKEDISMN SVPIQQETLV
VRRKHQGCSV SFQLEKVLVT VGCTCVTPVI HHVQ
Endotoxin: Less than 1EU/mg of rHuIL-17F as determined by LAL method.
Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 4 mM HCl to a concentration of 0.1mg/ml. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.
Storage: This lyophilized preparation is stable for several weeks at 2-8°C, but should be kept at -20°C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.
Usage: This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. Made in China
Description: Human IL-17F is synthesized as a 153 aa precursor with a 20 aa signal sequence and a 133 aa mature region. Like IL-17A, IL-17F contains one potential site for N-linked glycosylation. IL-17A and IL-17F share 50% aa sequence identity. IL17-F homodimer is produced by an activated subset of CD4+ T cells, termed Th17. IL17-F has been shown to stimulate proliferation and activation of T-cells and PBMCs. IL-17F also regulates cartilage matrix turnover and inhibits angiogenesis.